search
Back to results

Vaccination Adjuved Against Hepatitis B in SNS Workers Typed as no Responders to Conventional Vaccines

Primary Purpose

Hepatitis B, Hepatitis, Hepatitis, Viral, Human

Status
Completed
Phase
Phase 4
Locations
Spain
Study Type
Interventional
Intervention
Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).
Sponsored by
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Hepatitis B

Eligibility Criteria

18 Years - 64 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • NHS workers -including university students doing their internships in health centres dependent on the National Health System (inclusion of students is regulated and limited by specific instructions on labour prevention in each autonomous community).
  • Criteria defining them as NO responders to the conventional hepatitis B vaccine: anti HBsAb titers <10 mIU / ml following the application of six doses of conventional vaccine at 20 μg doses (two complete guidelines).

Exclusion Criteria:

  • Known allergy to the active substance or any of the other ingredients of the medicinal product (included in section 6 of the product data sheet).
  • Subjects that have ever had an allergic reaction to any vaccine against hepatitis B.
  • Subjects have a serious infection with fever.
  • Subjects for whom informed consent is not obtained.
  • Subjects that have not revoked the consent initially signed.

Sites / Locations

  • Hospital Universitario Puerta de Hierro
  • Complejo Asistencial Universitario de León
  • Hospital Universitario Gregorio Marañón
  • Hospital Universitario Ramón y Cajal
  • Hospital Clínico San Carlos
  • Hospital Universitario Fundación Jiménez Díaz
  • Hospital Universitario 12 de Octubre
  • Complejo Asistencial Universitario de Palencia
  • Complejo Asistencial Universitario de Salamanca
  • Hospital Clinico Universitario de Valladolid
  • Complejo Asistencial de Zamora

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Fendrix

Arm Description

The primary immunisation consists of 4 separate 0.5 ml doses of FENDRIX administered at the following schedule: 1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine

Outcomes

Primary Outcome Measures

Number of Participants With Protective Levels of Antibodies After Treatment
Measurement of antibody antiHBs: before the first dose and a month after the administration of each dose.

Secondary Outcome Measures

Full Information

First Posted
January 19, 2018
Last Updated
July 5, 2021
Sponsor
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Collaborators
Instituto de Investigación Biomédica de Salamanca, Spanish Clinical Research Networt (SCReN)
search

1. Study Identification

Unique Protocol Identification Number
NCT03410953
Brief Title
Vaccination Adjuved Against Hepatitis B in SNS Workers Typed as no Responders to Conventional Vaccines
Official Title
Vaccination Adjuved Against Hepatitis B in SNS Workers Typed as no Responders to Conventional Vaccines
Study Type
Interventional

2. Study Status

Record Verification Date
July 2021
Overall Recruitment Status
Completed
Study Start Date
April 13, 2018 (Actual)
Primary Completion Date
October 31, 2019 (Actual)
Study Completion Date
October 31, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Collaborators
Instituto de Investigación Biomédica de Salamanca, Spanish Clinical Research Networt (SCReN)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Health workers with biological risk in their tasks, who have been vaccinated as non-responders to conventional vaccination against Hepatitis B. To provide Health workers-staff with an additional protection tool against hepatitis B infection. To evaluate the efficacy of the adjuvanted vaccine in healthy nonresponders to conventional hepatitis B vaccine.
Detailed Description
An interventional, phase 4, single group assignment, without masking (open label), preventive clinical trial was carried out in health workers with biological risk in their tasks, who have been filed as non-responders to conventional vaccination against Hepatitis B. Methods: 67 health workers with biological risk in their tasks, who have been filed as non-responders to conventional vaccination against Hepatitis B, were enrolled in the Clinical Trial. All participants were from 18 years up to 64 years old. The criteria defining them as non-responders to the conventional hepatitis B vaccine is anti HBsAb titers < 10 mUI/ml following the application of six doses of conventional vaccine at 20 lg doses (two complete guidelines). The objective of this study was to provide Health workersstaff with an additional protection tool against hepatitis B infection, and to evaluate the efficacy of the adjuvanted vaccine in healthy non-responders to conventional hepatitis B vaccine.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatitis B, Hepatitis, Hepatitis, Viral, Human, Hepatitis B Immunization

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Model Description
non-responders to conventional treatment of hepatitis B vaccination and consent to participate
Masking
None (Open Label)
Allocation
N/A
Enrollment
67 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Fendrix
Arm Type
Experimental
Arm Description
The primary immunisation consists of 4 separate 0.5 ml doses of FENDRIX administered at the following schedule: 1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine
Intervention Type
Biological
Intervention Name(s)
Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).
Intervention Description
The primary immunisation consists of 4 separate 0.5 ml doses administered at the following schedule: 1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine
Primary Outcome Measure Information:
Title
Number of Participants With Protective Levels of Antibodies After Treatment
Description
Measurement of antibody antiHBs: before the first dose and a month after the administration of each dose.
Time Frame
Between 40 and 60 days after the last dose given

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: NHS workers -including university students doing their internships in health centres dependent on the National Health System (inclusion of students is regulated and limited by specific instructions on labour prevention in each autonomous community). Criteria defining them as NO responders to the conventional hepatitis B vaccine: anti HBsAb titers <10 mIU / ml following the application of six doses of conventional vaccine at 20 μg doses (two complete guidelines). Exclusion Criteria: Known allergy to the active substance or any of the other ingredients of the medicinal product (included in section 6 of the product data sheet). Subjects that have ever had an allergic reaction to any vaccine against hepatitis B. Subjects have a serious infection with fever. Subjects for whom informed consent is not obtained. Subjects that have not revoked the consent initially signed.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jose L. Bravo-Grande, MD PhD
Organizational Affiliation
IBSAL-Instituto de Investigación Biomédica de Salamanca
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Universitario Puerta de Hierro
City
Majadahonda
State/Province
Madrid
ZIP/Postal Code
28222
Country
Spain
Facility Name
Complejo Asistencial Universitario de León
City
León
ZIP/Postal Code
24080
Country
Spain
Facility Name
Hospital Universitario Gregorio Marañón
City
Madrid
ZIP/Postal Code
28007
Country
Spain
Facility Name
Hospital Universitario Ramón y Cajal
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Facility Name
Hospital Clínico San Carlos
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Hospital Universitario Fundación Jiménez Díaz
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Hospital Universitario 12 de Octubre
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Facility Name
Complejo Asistencial Universitario de Palencia
City
Palencia
ZIP/Postal Code
34005
Country
Spain
Facility Name
Complejo Asistencial Universitario de Salamanca
City
Salamanca
ZIP/Postal Code
37007
Country
Spain
Facility Name
Hospital Clinico Universitario de Valladolid
City
Valladolid
ZIP/Postal Code
47003
Country
Spain
Facility Name
Complejo Asistencial de Zamora
City
Zamora
ZIP/Postal Code
49022
Country
Spain

12. IPD Sharing Statement

Citations:
PubMed Identifier
33334613
Citation
Bravo-Grande JL, Asuncion Blanco-Gonzalez M, de la Torre-Robles JM, Asmat-Inostrosa MP, Fernandez-Escribano M, Villalobos IM, Covadonga Caso-Pita M, Hervella-Ordonez M, Canibano Cimas LM, de la Fuente-Martin JM, Luisa Rodriguez de la Pinta M, Olivas JRB, Munoz-Ruiperez C, Alonso Lopez MA, Del Campo MT, Antonieta Ramirez Perez M, Sanchez-Arcilla I, Marzola-Payares M, Rescalvo-Santiago F, Paula-Ortiz M, Sanchez-Santos JM, Lopez-Perez R. Vaccination adjuvated against hepatitis B in Spanish National Healthcare System (SNS) workers typed as non-responders to conventional vaccines. Vaccine. 2021 Jan 15;39(3):554-563. doi: 10.1016/j.vaccine.2020.12.006. Epub 2020 Dec 15.
Results Reference
derived

Learn more about this trial

Vaccination Adjuved Against Hepatitis B in SNS Workers Typed as no Responders to Conventional Vaccines

We'll reach out to this number within 24 hrs